Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience

Mussolin, Lara; Buldini, Barbara; Lovisa, Federica; Carraro, Elisa; Disarò, Silvia; Nigro, Luca Lo; dʼAmore, Emanuele S.G.; Pillon, Marta; Basso, Giuseppe

doi:10.1002/pbc.25607

Cited by 32 publications

(28 citation statements)

References 28 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…MDD was detected in 49% (32/65) of BM samples, whereas only 21% (14/65) were positive at standard morphological evaluation. Using an MDD cut‐off level of 3% by FCM, the 5‐year EFS was 60% for patients with MDD >3% LBL cells versus 83% for the remaining patients ( P = 0·04) (Mussolin et al , ). Additional prospective trials are needed to determine the level of significant MDD and the role of BM MRD in paediatric T‐LBL as prognostic markers.…”

Section: Prognostic Parameters Recurrent Genetic Alterations and Rismentioning

confidence: 99%

Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities

Burkhardt

Hermiston

2019

Br J Haematol

View full text Add to dashboard Cite

Lymphoblastic lymphoma (LBL) is the second most common type of Non-Hodgkin Lymphoma (NHL) in childhood and adolescence, accounting for 25-35% of all cases. The majority, 70-80%, is of T-lymphoblastic origin while 20-25% arise from B lymphoblasts. With current therapy, the event-free and overall survivals for paediatric LBL patients now exceeds 80%. Therapy, especially in T-LBL with large mediastinal tumours, is challenging, with both significant morbidity and late sequela. An additional challenge is the dismal prognosis of patients with refractory or relapsed disease. This review article will focus on the growing knowledge of the pathogenesis and biology of LBL, recent advances and challenges in the therapy of LBL, and ongoing and future efforts and opportunities in optimizing therapy and developing novel targeted treatment approaches.

show abstract

Section: Prognostic Parameters Recurrent Genetic Alterations and Rismentioning

confidence: 99%

Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities

Burkhardt

Hermiston

2019

Br J Haematol

View full text Add to dashboard Cite

show abstract

“…One study found that the 2-year EFS was shorter in children with minimal disseminated disease in the bone marrow ($1% T-LBL cells) than in those without (68.1% 6 11.1% vs. 90.7% 6 4.4%, p 5 0.031) [66]. Similarly, a recent Italian series of 52 children with T-LBL found that the 5-year EFS was shorter for patients with O3% LBL cells in the bone marrow than for patients below this cutoff (60.0% 6 22% vs. 83.0% 6 6%, p 5 0.049) [67]. Minimal residual disease status has been successfully used to select high-risk adult LBL patients for SCT [35].…”

Section: Minimal Disseminated Disease and Residual Diseasementioning

confidence: 87%

Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators

Leprêtre

Graux

Touzart

et al. 2017

Experimental Hematology

View full text Add to dashboard Cite

T-cell lymphoblastic lymphoma (T-LBL) is a rare, aggressive neoplasm of precursor T cells that occurs mostly in adolescents and young adults. In this review, we describe the treatment of adult T-LBL with a focus on recent advances using pediatric-inspired acute lymphoblastic leukemia regimens, which have greatly improved outcome. We also discuss the development of prognostic indicators for T-LBL, especially oncogenetic factors, that can identify patients at higher risk of relapse and may help further extend T-LBL patient survival. Pediatric-inspired acute lymphoblastic leukemia regimens have the potential to become the treatment of choice for adult T-LBL, and they might also reduce the need for other longstanding T-LBL interventions, particularly mediastinal irradiation and stem cell transplantation.

show abstract

“…In the future, FC may play an important role also in patients with existing mature B‐cell lymphomas by identifying low‐level B‐LBL cells in peripheral blood or bone marrow cells , which could be evaluated for IgH/BCL2 and “double hit” cytogenetic abnormalities. Early identification of these cells may herald an impending transformation of an existing or previously treated lymphoma and enable an early therapeutic intervention.…”

Section: Discussionmentioning

confidence: 99%

Immunophenotypic and cytogenetic findings of B‐lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement

Kelemen

Holden

Johnson

et al. 2016

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experience

Abstract: Our data demonstrated that MDD studied at diagnosis by MFC could represent a useful prognostic tool in childhood LBL and further application for better stratification is warranted.

Cited by 32 publications

References 28 publications

Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities

Lymphoblastic lymphoma in children and adolescents: review of current challenges and future opportunities

Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators

Immunophenotypic and cytogenetic findings of B‐lymphoblastic leukemia/lymphoma associated with combined IGH/BCL2 and MYC rearrangement

Contact Info

Product

Resources

About